Cost-effectiveness of FOLFOX6+Bevacizumab Versus FOLFOX6+Cetuximab in Stage IV Colorectal Cancer Patients in Shiraz, Iran.

Abdosaleh JafariSedighe Sadat Tabatabaei FarMehdi DehghaniRamin Ravangard

Published in: Cancer control : journal of the Moffitt Cancer Center (2023)

Considering that the FOLFOX6+Cetuximab regimen was more cost-effective, it is suggested to be prioritized in preparing clinical guidelines for Iranian colorectal cancer patients. In addition, increasing the basic and supplementary insurance coverage for this drug combination as well as the use of remote technology to guide patients by oncologists can be solutions to reduce direct and indirect costs of the patients.

Keyphrases

metastatic colorectal cancer
end stage renal disease
newly diagnosed
chronic kidney disease
ejection fraction
emergency department
prognostic factors
healthcare
patient reported outcomes
palliative care
patient reported